PDCD1 and lung carcinoma: As a well-known immune target, immunotherapy with the blockade of PD1 and its ligand PD-L1 can improve the survival time of patients with lung cancer (De Ruysscher et al., 2022) and colorectal cancer (Andre et al., 2020).